Insider · CIK 0001131148
Harry Penner Jr
Files at CLDX (Celldex Therapeutics, Inc.). First filing -, latest -.
Harry Penner Jr files SEC Form 4 as director at CLDX (Celldex Therapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Harry Penner Jr has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 2 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 25, 2026 | CLDX Celldex Therapeutics, Inc. | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +26,000 | $0.00 | $0 | 26,000 | Jun 29, 2026 |
| Jun 5, 2025 | CLDX Celldex Therapeutics, Inc. | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +16,500 | $0.00 | $0 | 16,500 | Jun 9, 2025 |
Questions about Harry Penner Jr
Answered from the filings on this page, as of the latest one.
Is Harry Penner Jr buying or selling?
Harry Penner Jr has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Harry Penner Jr's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Harry Penner Jr has 0.
Where does Harry Penner Jr file Form 4?
Harry Penner Jr has filed Form 4 at CLDX (Celldex Therapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.